New drug combo aims to shrink lung tumors before surgery in targeted trial

NCT ID NCT07153770

Not yet recruiting Disease control Sponsor: Shanghai Pulmonary Hospital, Shanghai, China Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests whether the targeted drug bozitinib, combined with standard chemotherapy, can shrink tumors before surgery in people with stage IIA to IIIC non-small cell lung cancer that has a specific MET gene change. About 34 participants will receive the drug combo for 8 weeks, then have surgery to remove any remaining cancer. The main goal is to see how many patients have a major response in their tumor tissue after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Bozitinib (a targeted cancer drug) combined with standard chemotherapy
What this could lead to: If successful, this could offer a more effective way to shrink MET-altered lung cancers before surgery, potentially improving long-term survival and reducing recurrence.
What could go wrong: This is a small, early-phase trial with only 34 participants. The combination may cause significant side effects, and it is not yet known if it will work better than standard treatment alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MET ACTIVATING MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MET ACTIVATING MUTATION MET EXON 14 MUTATION NSCLC

More trials for these conditions

Other studies related to the condition(s) this trial covers.